ArticleBMC health services research2026
Structural drivers of drug shortages and market withdrawal: a longitudinal analysis of the Romanian pharmaceutical market.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug supply discontinuities and market withdrawals represent a general structural weakness of national healthcare systems, with direct effects on therapeutic adherence and the equity of treatment access. This study investigates the longitudinal dynamics of shortages and drug withdrawal.
methodsWe constructed an annual dataset (2017-2024) from official national records and applied an Interrupted Time Series (ITS) analysis for shortages (as a rate adjusted to the number of Rx products), withdrawals, and SNAs, considering 2020 as the intervention point. To identify predictors of permanent shortages, we performed an observational analysis at the episode level (N = 603) and estimated a bias-reduced (Firth) logistic regression model. In parallel, we assessed the market longevity for 74,559 product-year observations (2008-2024), identifying 16,638 withdrawals and estimating a Cox model with time-dependent effects and frailty terms at the INN level.
resultsThe ITS outcome points to a boost in shortages before the pandemic, a sharp drop in 2020, followed by a return to the upward trend with no statistically significant change in the post-COVID slope. The lag analysis suggests that episodes of shortage precede permanent withdrawals by an average interval of approximately two years. The Firth regression shows that generic status reduces the probability of permanent shortage compared to innovative products, and ATC M and N therapeutic classes are associated with a lower probability of permanence. In the survival analysis, the risk of market withdrawal increases with intensified competition within the same therapeutic group defined by INN and with higher prices for the same active substance, and generic and biosimilar products have a higher hazard of withdrawal than innovative products, with attenuation over time.
conclusionDrug shortages in Romania reflect market fragility that predated the pandemic. The results support the necessity of moving from reactive policies to predictive surveillance and price reforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.